Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 6, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 15.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 6, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2028 | LYL273 for Patients With Relapsed or Refractory mCRC | Trial Milestone | Phase 1/Phase 2 |
| December 31, 2028 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Trial Milestone | Phase 1/Phase 2 |
| December 15, 2029 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Trial Milestone | Phase 3 |
Track LYEL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LYEL in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.